Cited by 205Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome

Open access

Murphy, Sabina A., Cannon, Christopher P., Blazing, Michael A., Giugliano, Robert P., White, Jennifer A., Lokhnygina, Yuliya, Reist, Craig, Im, KyungAh, Bohula, Erin A., Isaza, Daniel, Lopez-Sendon, Jose, Dellborg, Mikael, Kher, Uma, Tershakovec, Andrew M., Braunwald, Eugene·2016·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2015.10.077

Open this paper in CoChat — free account Open PDF

Abstract

Background Intensive low-density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) significantly reduced the first primary endpoint (PEP) in patients post-acute coronary syndrome (ACS) compared to placebo/simvastatin.Objectives This analysis tested the hypothesis that total events, including those beyond the first event, would also be reduced with ezetimibe/simvastatin therapy.Methods All PEP events (cardiovascular [CV] death, myocardial infarction [MI], stroke, unstable angina [UA] leading to hospitalization, coronary revascularization ≥30 days post-randomization) during a median 6-year follow-up were analyzed in patients randomized to receive ezetimibe/simvastatin or placebo/simvastatin in IMPROVE-IT. Negative binomial regression was used for the primary analysis.Results Among 18,144 patients, there were 9,545 total PEP events (56% were first events and 44% subsequent events). Total PEP events were significantly reduced by 9% with ezetimibe/simvastatin vs placebo/simvastatin (incidence-rate ratio [RR]: 0.91; 95% confidence interval [CI]: 0.85 to 0.97; p = 0.007), as were the 3 pre-specified secondary composite endpoints and the exploratory composite endpoint of CV death, MI, or stroke (RR: 0.88; 95% CI: 0.81 to 0.96; p = 0.002). The reduction in total events was driven by decreases in total nonfatal MI (RR: 0.87; 95% CI: 0.79 to 0.96; p = 0.004) and total NF stroke (RR: 0.77; 95% CI: 0.65 to 0.93; p = 0.005).Conclusions Lipid-lowering therapy with ezetimibe plus simvastatin improved clinical outcomes. Reductions in total PEP events, driven by reductions in MI and stroke, more than doubled the number of events prevented compared with examining only the first event. These data support continuation of intensive combination lipid-lowering therapy after an initial CV event. (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial [IMPROVE-IT]; NCT00202878).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2015.10.077

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citation
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868

Flagged first, then by citations

Show all 25 references

Sorted by citations

Items 101–200 of 204

Secondary Prevention in Lower Extremity Artery Disease Patients: Lipid-Lowering Therapy and Long-Term Guideline Adherence
Mueller, L., Engelbertz, C. M., Reinecke, H., Freisinger, E., Malyar, N. M., Meyborg, M., Brix, T. J., Varghese, J., & Gebauer, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226838 · Cited by 11
The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development
Davidson, M. H., Hsieh, A., Dicklin, M. R., & Maki, K. C. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.12.005 · Cited by 14
Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease
Suh, D., Griggs, S. K., Henderson, E. R., Lee, S.-M., & Park, T. (2017) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1407246 · Cited by 11
Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review
Chen, C., Wei, F., Dong, Y., & Liu, C. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07587-9 · Cited by 10
Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018)
Arrieta, F., Iglesias, P., Pedro‐Botet, J., Becerra, A., Ortega, E., Obaya, J. C., Nubiola, A., Maldonado, G. F., Campos, M. D. M., Petrecca, R., et al. (2018) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2018.05.002 · Cited by 10
Preventive Therapies in Peripheral Arterial Disease
Shah, A. J., Pavlatos, N., & Kalra, D. K. (2023) · Biomedicines · doi:10.3390/biomedicines11123157 · Cited by 12
PCSK9 inhibitors in the current management of atherosclerosis
Whayne, T. F. (2016) · Archivos de cardiología de México · doi:10.1016/j.acmx.2016.11.013 · Cited by 11
High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes
Androulakis, E. S., Zacharia, E. M., Παπαγεωργίου, Ν., Lioudaki, E., Bertsias, D., Charakida, M., Siasos, G., & Tousoulis, D. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170209145622 · Cited by 10
NPC1L1-dependent transport of 27-alkyne cholesterol in intestinal epithelial cells
Ticho, A. L., Calzadilla, N., Malhotra, P., Lee, H., Anbazhagan, A. N., Saksena, S., Dudeja, P. K., Lee, D., Gill, R. K., & Alrefai, W. A. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00062.2021 · Cited by 10
Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*
Borissov, B., Urbich, M., Georgieva, B., Tsenov, S., & Villa, G. (2017) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2017.1412753 · Cited by 10
Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease
Heinrich, N. S., Pedersen, R. P., Vestergaard, M. B., Lindberg, U., Andersen, U. B., Haddock, B., Hansen, T. W., Fornoni, A., Larsson, H. B. W., & Rossing, P. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15146 · Cited by 9
Prevention of Carotid Artery Atherosclerosis: What is the Evidence?
Whayne, T. F. (2016) · Angiology · doi:10.1177/0003319716669460 · Cited by 9
Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future
Faluk, M. A., Wardhere, A., Mohamoud, A. A., Nor, M. A., Bampastsias, D., Oikonomou, E., Almubaid, Z., & Hemyari, B. A. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102637 · Cited by 8
Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease)
Fras, Z., & Mikhailidis, D. P. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118999200727224946 · Cited by 8
Pharmacological secondary prevention in patients with mesenterial artery atherosclerosis and arterial embolism
Gottsäter, A. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.07.004 · Cited by 8
Advances in Primordial, Primary, and Secondary Prevention of Stroke in Diverse Populations
Adeniji, O. A., Olowoyo, P., Akinyemi, R., Fisher, M., & Owolabi, M. O. (2024) · Stroke · doi:10.1161/strokeaha.123.044231 · Cited by 7
Dyslipidemia: Current Therapies and Strategies to Overcome Barriers for Use
DePhillips, C., Parikh, P. B., & Stevens, G. (2021) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2021.08.012 · Cited by 7
Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i
Mackinnon, E. S., Har, B., Champsi, S., Wani, R. J., Geyer, L., Shaw, E., Farris, M. S., & Anderson, T. J. (2023) · Cardiology and Therapy · doi:10.1007/s40119-022-00300-7 · Cited by 7
Prevalence of high-risk cardiovascular patients with therapy-resistant hypercholesterolemia
Kostev, K., Parhofer, K. G., & Dippel, F. W. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000098 · Cited by 7
LDL cholesterol: lower, faster, younger?
Berberich, A. J., & Hegele, R. A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30389-4 · Cited by 7
Leukocyte Rho kinase activity and serum cystatin C affect cardiovascular events in acute coronary syndrome
Ma, L., Dai, W., Lin, Y., Zhang, Z., Pan, Y., Han, H., Jia, H., Peng, J., Zhao, J., & Xu, L. (2020) · Medicine · doi:10.1097/md.0000000000020060 · Cited by 7
Peripheral Artery Disease and African Americans: Review of the Literature
Solaru, K. W. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0621-1 · Cited by 6
The effect of cold exposure on serum cholesterol is dependent upon ApoE
He, F., Su, W., Wu, R., Li, H., Lou, L., Wu, A., Xie, L., Du, Y., & Wu, S. (2021) · Journal of Thermal Biology · doi:10.1016/j.jtherbio.2021.102972 · Cited by 6
Monoclonal Antibodies for Lipid Management
Feinstein, M. J., & Lloyd‐Jones, D. M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0593-2 · Cited by 6
Latest Updates on Lipid Management
Egom, E. E. A., Pharithi, R. B., Hesse, S., Starr, N., Armstrong, R. L., Sulaiman, H. M., Gazdíková, K., Mozos, I. M., Čaprnda, M., Kubatka, P., et al. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00306-8 · Cited by 5
Lipids: a personal view of the past decade
Katsiki, N., & Mikhailidis, D. P. (2018) · HORMONES · doi:10.1007/s42000-018-0058-9 · Cited by 6
Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options
Demarchi, A., Somaschini, A., Cornara, S., & Androulakis, E. S. (2020) · Current Pharmaceutical Design · doi:10.2174/1389201021666201126143217 · Cited by 7
The year in cardiology 2016: Acute coronary syndromes
Crea, F., Binder, R. K., & Lüscher, T. F. (2017) · Srce i krvni sudovi · doi:10.5937/siks1701011c · Cited by 6
PROVE-IT to IMPROVE-IT
Wright, R. S., & Murphy, J. G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.016 · Cited by 7
More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial)
Katsiki, N., Athyros, V. G., & Mikhailidis, D. P. (2016) · HORMONES · doi:10.1007/bf03401397 · Cited by 6
Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study
de Vries, T. I., Westerink, J., Bots, M. L., Asselbergs, F. W., Smulders, Y. M., & Visseren, F. L. J. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-038881 · Cited by 5
Ezetimibe and atherosclerotic cardiovascular disease: a systematic review and meta-analysis
Omidi, F., Rahmannia, M., Bonjar, A. H. S., Mohammadsharifi, P., Nasiri, M. J., & Sarmastzadeh, T. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1269172 · Cited by 5
PENELOPE 1-year follow-up: legacy effect of a short protocol-led LDL-C-lowering strategy in patients after myocardial infarction
van der Brug, S., Trier, T. J. V., Khader, A. O., Liem, A. H., Schut, A., Martens, F. M. A. C., Alings, M., & the PENELOPE investigators (2025) · Netherlands Heart Journal · doi:10.1007/s12471-025-01939-2 · Cited by 5
Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry)
Puymirat, É., Aïssaoui, N., Lemesle, G., Cottin, Y., Coste, P., Schiele, F., Ferrières, J., Simon, T., & Danchin, N. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.11.032 · Cited by 5
Ezetimibe Monotherapy Reduces Serum Levels of Platelet-Activating Factor Acetylhydrolase in Patients With Dyslipidemia
Tano, K., Suematsu, Y., Tashiro, K., Kumagai-Koyanagi, N., Matsuo, Y., Kuwano, T., Miura, S., & Zenith Trial Investigators (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3901 · Cited by 5
Diabetes mellitus y riesgo cardiovascular: actualización de las recomendaciones del Grupo de Trabajo de Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED, 2021)
Arrieta, F., Pedro‐Botet, J., Iglesias, P., Obaya, J. C., Montánez, L., Maldonado, G. F., Becerra, A., Navarro, J., Perez, J. C., Petrecca, R., et al. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.05.002 · Cited by 15
Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance
Ward, N. C., Reid, C. M., & Watts, G. F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1060252 · Cited by 5
An Evidence-Based Guideline for Treating Dyslipidemia in Statin-Intolerant Patients
Lempp, D. (2021) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2021.06.005 · Cited by 5
2024 Egyptian consensus statement on the role of non-statin therapies for LDL cholesterol lowering in different patient risk categories
Taha, H., Kandil, H., Badran, H. M., Farag, N. M., Khamis, H., Nasr, G. M., Samy, M., Abdrabou, M., Abuelezz, M., & Shaker, M. M. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00562-7 · Cited by 5
Management and Treatment of Carotid Stenosis: Overview of Therapeutic Possibilities and Comparison Between Interventional Radiology, Surgery and Hybrid Procedure
Aliotta, L., Gavazzi, L. M., Malfa, P., Foti, P. V., Palmucci, S., Greco, M. C. L., Spatola, C., Inì, C., Tiralongo, F., Castiglione, D., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15131679 · Cited by 4
The year in cardiology 2016: acute coronary syndromes
Crea, F., Binder, R. K., & Lüscher, T. F. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw620 · Cited by 4
Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease
Packard, C. J., Young, R., Ross, K., Ford, I., Ambegaonkar, B. M., Brudi, P., & McCowan, C. (2017) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcx012 · Cited by 4
The position of Polish experts on conservative management in patients with artery diseases of lower limbs
Krasiński, Z., Gaciong, Z. A., Szymański, F. M., Kowalewski, R., & Urbanek, T. (2019) · Acta Angiologica · doi:10.5603/aa.2019.0007 · Cited by 4
Outcome of patients with prior coronary bypass surgery admitted with an acute coronary syndrome
Marcuschamer, I., Zusman, O., Iakobishvili, Z., Assali, A. R., Assa, H. V., Goldenberg, I., Cohen, T., Nir, S., Kornowski, R., & Eisen, A. (2021) · Heart · doi:10.1136/heartjnl-2020-318047 · Cited by 4
Barriers to prescribing proprotein convertase subtilisin‐kexin type 9 inhibitors after coronary revascularisation
Nguy, J., Hitchen, S. A., Lan, N. S. R., Dwivedi, G., Larbalestier, R. I., Yeap, B. B., & Fegan, P. G. (2022) · Internal Medicine Journal · doi:10.1111/imj.15700 · Cited by 4
Lipoprotein(a)—When to Screen and How to Treat
Patel, N., Mittal, N., Choubdar, P. A., & Taub, P. R. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00698-8 · Cited by 4
PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab
Bruckert, É., Kereiakes, D. J., Koren, M. J., Louie, M. J., Letierce, A., Miller, K., & Cannon, C. P. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.005 · Cited by 4
Self-citation
Investigational therapies for hypercholesterolemia
TOMKIN, G. H., & Owens, D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1315407 · Cited by 4
More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial)
Katsiki, N., Athyros, V. G., & Mikhailidis, D. P. (2016) · HORMONES · doi:10.14310/horm.2002.1658 · Cited by 4
Sekundärdatenanalyse zur Ermittlung der Prävalenz von kardiovaskulären Hochrisiko-Patienten mit Hypercholesterinämie und therapierefraktärem Behandlungsverlauf
Dippel, F. W., Parhofer, K. G., Müller-Bohn, T., Gebhardt, S., & Kostev, K. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-123977 · Cited by 3
Effect of simvastatin on expression of VEGF and TGF-β1 in atherosclerotic animal model of type�2 diabetes mellitus
Wang, H., Li, J., Fu, X., Liu, Y., Xu, Q., & Sang, L. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6583 · Cited by 3
Time to Make a Change: Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine
Pallazola, V. A., Quispe, R., Elshazly, M. B., Vakil, R. M., Sathiyakumar, V., Jones, S. R., & Martin, S. S. (2018) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-018-0590-9 · Cited by 3
Peripheral artery disease: advances in medical therapy
Garagoli, F., Slipczuk, L. N., Shapiro, M. D., Bonaca, M. P., & Bhatt, D. L. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag516 · Cited by 3
Time for new low density lipoprotein cholesterol (LDL-C) targets?
Daskalopoulou, S. S., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1369957 · Cited by 2
Hypercholesterinämie – Wo stehen wir heute? Wo wollen wir hin?
Gitt, A. K., & Zahn, R. (2016) · Herz · doi:10.1007/s00059-016-4457-x · Cited by 2
Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins, and Plant Sterols
Dayspring, T. D., & Pokrywka, G. S. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_13 · Cited by 2
Applications of long-lasting and implantable drug delivery systems for cardiovascular disease treatment
Khalaj, R., & Douroumis, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821749-8.00004-5 · Cited by 2
Are clinical trial results transferable in the real life?
Natale, E., & Marsocci, A. (2016) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2015.733 · Cited by 2
Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease
Mascitelli, L., & Goldstein, M. R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.084 · Cited by 2
Endothelial function in high-risk patients with ezetimibe therapy
Günes-Altan, M., Bosch, A., Striepe, K., Schiffer, M., Achenbach, S. S., Schmieder, R. E., & Kannenkeril, D. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.07.001 · Cited by 1
Cross-Sectional Retrospective Observational Study on Lipid-Lowering Therapy for Secondary Prevention in Patients with Peripheral Arterial Disease: LEONIDA Registry
Radano, I., Delnevo, F., Aranzulla, T. C., Piazza, S., Rosa, C. D., Muccioli, S., Trucco, M. C. F., Ricotti, A., Quaglino, S., Ferri, M., et al. (2025) · Journal of Vascular Diseases · doi:10.3390/jvd4030027 · Cited by 1
Physical Therapist Management of Cardiovascular Diseases
Ahmed, A. S., Balogun, J. A., & Balogun, O. I. (2026) · Springer eBooks · doi:10.1007/978-3-031-86558-9_21 · Cited by 1
“Strike Early and Strike Strong”: Low LDL-Cholesterol and Low Albumin Predict Statin Hyporesponsiveness in Acute Coronary Syndrome
Uslu, S., & Öztekin, G. M. Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062312 · Cited by 1
Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study
Nicolau, J. C., Murphy, S. A., Giugliano, R. P., Leiter, L. A., Ferrari, G. M. D., Park, J., Kuder, J., Liu, L., Wang, H., Shastri-Kumar, V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.015 · Cited by 1
Self-citation
Editor-in-Chief’s Top Picks From 2015: Part One
Fuster, V. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.002 · Cited by 1
Defining Potential Use of Nonstatin Therapies to Lower Blood Cholesterol Levels
Smith, S. C. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2290 · Cited by 1
Can we achieve ESC 2019 guidelines LDL-cholesterol target in Tunisia?
Elhadj, Z. I., Cherif, N., Bennour, E., Antit, S., Echaieb, W., Zakhama, L., & Kachboura, S. (2022) · PubMed Central · Cited by 1
Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics
Bashir, B., Iqbal, Z., Schofield, J. D., & Soran, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00012-7 · Cited by 1
Profile of use and access to statins in patients with coronary arterial disease in an outpatient clinic of a teaching hospital
Veloso, R. C. D. S. G., Cruzeiro, M. G. M., Dias, B. M., & Reis, A. M. M. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1793313 · Cited by 1
Hemodynamic impact of positive end expiratory pressure in right cardiac performance
Vinko Tomicic, F. (2019) · Journal of Cardiology & Current Research · doi:10.15406/jccr.2019.12.00455 · Cited by 1
Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021)
Arrieta, F., Pedro‐Botet, J., Iglesias, P., Obaya, J. C., Montánez, L., Maldonado, G. F., Becerra, A., Navarro, J., Perez, J. C., Petrecca, R., et al. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.01.005 · Cited by 1
Trendi v sekundarni preventivi po srčnem infarktu – umestitev novosti
Veselič, M. T., & Šabović, M. (2022) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3169
Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment
Sykes, A. V., Patel, N., Lee, D. H., & Taub, P. R. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01775-5 · Cited by 2
Reply
Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., Tershakovec, A. M., & D, E. B. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.580 · Cited by 1
Self-citation
Reply
Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., Tershakovec, A. M., & D, E. B. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.04.043 · Cited by 1
Self-citation
Is Total Risk Management an Answer for Better Prognosis in Diabetic Patients?
Sakakura, K. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed050
Intérêt de l’anatomie et de l’imagerie coronaire dans l’évaluation du risque résiduel chez le patient post-syndrome coronarien aigu
Rioufol, G., Dérimay, F., & Finet, G. (2016) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2016.06.004
Clinical investigation of subclinical vascular disease in psychosocial stress and dyslipidaemia
Ellins, E. A. (2016) · ORCA Online Research @Cardiff (Cardiff University)
MAIN APPROACHES TO DYSLIPIDEMIA TREATMENT ACCORDING TO INTERNATIONAL GUIDELINES 2015–2016 YEARS
Bagriy, A. E., Mv, K., Tsiba, I., Ефременко, В. А., Shchukina, E. V. S., Приколота, О. А., & Vlasenko, A. I. (2017) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2017-1-4-11
Statin and ezetimibe combination therapy: New therapeutic options for lowering Low-Density Lipoprotein Cholesterol
Lin, X., & Liu, M. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.06.118
The year in cardiology 2016: acute coronary syndromes
Crea, F., Binder, R. K., & Lüscher, T. F. (2017) · Cardiologia Croatica · doi:10.15836/ccar2017.200
PAVK der unteren Extremitäten – konservative und antithrombotische Therapie
Linnemann, B., Schulz, M., Schierling, W., & Pfister, K. (2018) · Gefäßmedizin Scan - Zeitschrift für Angiologie Gefäßchirurgie diagnostische und interventionelle Radiologie · doi:10.1055/a-0730-2220
Are there caveats in a treatment of CAD?
Kovárník, T. (2018) · Interní medicína pro praxi · doi:10.36290/int.2018.023
Familial hypercholesterolemia: clinical pearls
Hydoub, Y. M. (2019) · Journal of Cardiology & Current Research · doi:10.15406/jccr.2019.12.00454
Lipid-lowering therapy in special situations
Ватутин, Н. Т., Тарадин, Г. Г., Rakitskaya, I. V., Kharchenko, A. V., Stekhina, K. V., Linnik, I. G., Борт, Д. В., Гасендич, Е. С., & Mogilevskaya, K. E. (2021) · Health Food & Biotechnology · doi:10.36107/hfb.2020.i4.s88
Risk factors and pharmacological therapy in patients with vascular disease
Maiolino, G., Rossato, M., & Vettor, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822113-6.00021-8
Traitement médical de l’artériopathie athéromateuse des membres inférieurs
Sitruk, J., Goudot, G., Mohamedi, N., & Messas, E. (2021) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2021.11.007
Editor-in-Chief’s Top Picks From 2016: Part Two
Fuster, V. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.005
Aggressive treatment of LDL-cholesterol and patients undergoing CABG: news from IMPROVE-IT
Mikhailidis, D. P., & Nair, D. R. (2016) · Clinical Lipidology · doi:10.1080/17584299.2016.1254432
A Brief Overview of Medical Management Options in Peripheral Arterial Disease
(2021) · International Journal of Infectious Diseases and Research · doi:10.47485/2693-2326.1021
Lipids
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch12
Risk Factors of Patients with Peripheral Arterial Disease
Gimbel, M. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-031-09741-6_2
Genetic Risk Stratification Will Enhance Primary Prevention of Coronary Artery Disease
Roberts, R., & Acuna, E. (2023) · Medical Research Archives · doi:10.18103/mra.v11i7.1.4063
Treatment of dyslipidemia in acute coronary syndrome
Yadav, S., & Sawhney, J. P. S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.011 · Cited by 1
Dyslipidaemia in geriatric patients
Majumder, A. A. S. (2024) · Cardiovascular Journal · doi:10.3329/cardio.v16i2.75210
Was ist neu im Management der peripheren arteriellen Verschlusskrankheit und der aortalen Erkrankungen?
Schulze-Bauer, H., Staudacher, M., Steiner, S., & Schlager, O. (2024) · Herz · doi:10.1007/s00059-024-05286-7
Novel therapies for lowering low-density lipoprotein levels for atherosclerotic cardiovascular disease prevention: reaching the target where others have failed
Dziewierz, A., Bobrowska, B., Streb, W., Pelliccia, F., Bartuś, S., & Rajtar-Salwa, R. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2570839
Risk Factors for Claudication and Management to Modify Them
Devadoss, R., & Alonso, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-02460-2_7
Contemporary Medical Management of Carotid Artery Stenosis
Salameh, M., & Ratchford, E. V. (2026) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2026.01.001

Authors: Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., White, J. A., Lokhnygina, Y., Reist, C., Im, K., Bohula, E. A., Isaza, D., Lopez-Sendon, J., Dellborg, M., Kher, U., Tershakovec, A. M., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
Duke University (US)
Institute of Cardiology (CO)
Hospital Universitario La Paz (ES)
Sahlgrenska University Hospital (SE)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author: Murphy, Sabina A.
ORCID: Murphy, Sabina A.
Cannon, Christopher P.
Giugliano, Robert P.
White, Jennifer A.
Bohula, Erin A.
Isaza, Daniel
Lopez-Sendon, Jose
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2016-02
Volume: 67
Issue: 4
Pages: 353-361
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2015.10.077
OpenAlex: W2251889296
Cited by: 205
References: 25
Citations by year: 2026: 9 · 2025: 8 · 2024: 13 · 2023: 8 · 2022: 12 · 2021: 26 · 2020: 18 · 2019: 25 · 2018: 21 · 2017: 30 · 2016: 35
FWCI: 40.95
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 367 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Funders: GlaxoSmithKline
Amarin Corporation
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: ezetimibe, simvastatin, ezetimibe/simvastatin, acute coronary syndrome, IMPROVE-IT trial, cardiovascular events, LDL cholesterol lowering, lipid-lowering therapy, myocardial infarction, stroke, cardiovascular mortality, secondary prevention, combination therapy, negative binomial regression, incidence rate ratio, coronary revascularization
MeSH terms: Ezetimibe, Aged, Anticholesteremic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Time Factors, United States, Incidence, Survival Rate, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Acute Coronary Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks